

# RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells

JUN-FENG CHEN<sup>1</sup>, BI-XIA YU<sup>1</sup>, LIANG MA<sup>1,2</sup>, XIU-YI LV<sup>1</sup>, JUN-HUI JIANG<sup>1,2</sup> and QI MA<sup>1-3</sup>

<sup>1</sup>Translational Research Laboratory for Urology, The Key Laboratory of Ningbo;

<sup>2</sup>Department of Urology, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010; <sup>3</sup>Department of Urology, The Ninth Hospital of Ningbo, Ningbo, Zhejiang 315020, P.R. China

Received August 4, 2017; Accepted January 19, 2018

DOI: 10.3892/ol.2018.8135

Abstract. Tyrosine kinase receptor macrophage stimulating 1 receptor (MST1R, also known as RON) contributes to the transformation and malignant progression observed in epithelial cells. The purpose of the present study is to assess the value of RON as a potential target in bladder cancer (BC) therapeutics. The expression profile of RON in BC tissues and adjacent noncancerous tissues was detected via immunohistochemistry. The rate of positive RON expression differed significantly between bladder urothelial cancer tissues (54.7%) and paraneoplastic tissues (29.4%) (P<0.05). RON expression was positively associated with the number of tumors per patient, histological grading, pathological stage and distant metastasis (all P<0.05). Downregulation of RON expression using small interfering RNAs inhibited cell growth, cell migration and promoted cell apoptosis in the 5637 cell line. RON inhibition induced cell cycle arrest at the G<sub>1</sub>/S boundary following an increase of cyclin-dependent kinase inhibitor 1B and cyclin-dependent kinase inhibitor 1A, and a decrease of cyclin D1, cyclin D3 and cyclin-dependent kinase 4 expression. Furthermore, knockdown of RON significantly blocked signal transduction, including downstream protein kinase B and mitogen-activated protein kinase pathways. These results indicated that RON serves a notable role in BC and is a potential target of therapeutic intervention.

\*Contributed equally

### Introduction

Bladder cancer (BC) is one of the most common types of cancer globally, with high morbidity and mortality rates (1). The incidence of BC is increasing in much of the world (1); however, few novel approaches for the treatment of this disease have been developed in the past two decades (2). Only programmed cell death (PD) 1/PD-ligand 1 based immuno-therapy has displayed promising results for the management of BC in recent years (3). Cisplatin-based combination chemo-therapy remains the preferred first-line treatment for advanced or metastatic BC (4). Limited progress in improving outcomes has created a major incentive for the analysis of molecular alterations in BC, the identification of novel potential targets and to accelerate the identification of novel treatments for this disease (5).

Macrophage stimulating 1 receptor (MST1R, also known as RON) is a membrane tyrosine kinase receptor that has been considered to be a valuable target in cancer therapy (6). Elevated RON expression has been detected in a number of malignant tumor types, including those of the colon, breast and pancreas (7-9). RON overexpression has been reported to have prognostic value in predicting patient survival and clinical outcome in these types of cancer (7-9). The roles served by RON in BC have been studied extensively in vitro and in vivo, and results have demonstrated that RON and other tyrosine kinase receptors, including epidermal growth factor receptor and MET, exerted their effects collaboratively in BC carcinogenesis (10,11). Furthermore, macrophage-stimulating protein, which is the only known ligand of RON, was also detected in human urine samples (11). These results indicated that RON serves a key role in the development and progression of BC.

The results of the previous study indicated that the inhibition of RON by its specific monoclonal antibody (mAb) zt/g4 in human BC cell lines lead to reduced cell growth and motility, which provided evidence that RON is a potential target in BC (11). In the present study, the expression of RON tyrosine kinase receptor was further assessed via immunohistochemistry (IHC) in human BC tissues and adjacent noncancerous tissues. Furthermore, the effect of RON on BC cell proliferation, apoptosis and migration was also analyzed via the knockdown of RON expression with specific small interfering RNAs (siRNAs).

*Correspondence to:* Dr Jun-Hui Jiang or Dr Qi Ma, Translational Research Laboratory for Urology, The Key Laboratory of Ningbo, Ningbo First Hospital, The Affiliated Hospital of Ningbo University, 59 Liuting Street, Ningbo, Zhejiang 315010, P.R. China E-mail: junhui.jiangnb@yahoo.com E-mail: qi\_ma@yahoo.com

*Key words:* bladder cancer, receptor tyrosine kinase, apoptosis, cell cycle

6548

## Materials and methods

Main reagents. Cell Counting Kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies, Inc. (Dojindo laboratories, Inc., Kumamoto, Japan). Mouse mAb zt/f2 specific to RON immunoglobulin, plexins and transcriptional factor domain and rabbit antibody R5029 (specific to the RON C-terminal peptide) were provided by Professor Yao (Laboratory of Cancer Biology and Therapeutics, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China). The primary antibodies rabbit anti- $\beta$ -actin (cat. no. 4970; dilution, 1:1,000), anti-p38 (cat. no. 8690; dilution, 1:1,000), anti-phospho-p38 (cat. no. 4511; dilution, 1:1,000), anti-extracellular signal-regulated kinase 1/2 (ERK1/2) (cat. no. 9102s; dilution, 1:1,000), anti-phospho-ERK1/2 (cat. no. 4370s; dilution, 1:1,000), anti-protein kinase B (Akt) (cat. no. 4685s; dilution, 1:1,000), anti-phospho-Akt (cat. no. 4060s; dilution, 1:1,000), anti-cyclin D1 (cat. no. 2978; dilution, 1:1,000), anti-cyclin D3 (cat. no. 2936; dilution, 1:2,000), anti-cyclin-dependent kinase 4 (CDK4; cat. no. 12790; dilution, 1:1,000), anti-cyclin dependent kinase inhibitor 1A (p21) (cat. no. 2947; dilution, 1:1,000) and anti-cyclin dependent kinase inhibitor 1B (p27) (cat. no. 3686; dilution, 1:1,000) were all purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Fetal bovine serum (FBS), RPMI-1640, L-glutamine and penicillin were purchased from Thermo Fisher Scientific, Inc. (Waltham, MA, USA).

*Tissue collection and ethics statement*. Specimens from patients with BC (n=106) were obtained during surgical tumor resection in the Ningbo First Hospital (Ningbo, China) and with pathological identification in the Ningbo Diagnostic Pathology Center (Ningbo, China) between March 2011 and July 2014. Of the total patients, there were 87 males and 19 females, aged between 35 and 84 years old (mean age, 68 years old). The available adjacent non-cancerous samples were also obtained 1.5 cm away from the cancer tissues and confirmed by pathologists. None of the patients had undergone chemotherapy or radiotherapy prior to surgery. The present study was reviewed and approved by the Ethical Committee of Ningbo First Hospital (Ningbo, China) and all patients provided written informed consent prior to sample collection.

IHC and scoring. The tissue samples were fixed with 4% paraformaldehyde for 24 h at room temperature, embedded in paraffin and  $4-\mu$ m thick sections were prepared. Following deparaffnization with xylene and ethanol (100% ethanol for 5 min, 95% ethanol for 3 min, 85% ethanol for 3 min and 70% ethanol (Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) for 3 min, the tissue sections were incubated for 30 min at room temperature in 0.3% H<sub>2</sub>O<sub>2</sub> to block endogenous peroxidase activities. For antigen retrieval, samples were incubated with 0.1 M citrate buffer (pH 6.0) (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) in boiling water for 10 min. Following rinsing in PBS, non-specific antigens were blocked by 3% normal bovine serum (Beijing Solarbio Science & Technology Co., Ltd.,) for 15 min at room temperature, the slides were incubated with the anti-RON antibody zt/f2 used at a 1:200 dilution at 4°C overnight and subsequently incubated with anti-mouse IgG (H+L) antibody (cat. no. ab6789, dilution, 1:500; Abcam, Cambridge, MA, USA) for 1 h at room temperature. Detection was performed using an EnVision system according to the manufacturers protocol (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) and visualized with diaminobenzidine as substrate.

Six views were observed per slide and 100 cells were examined per view at x400 magnification under a light microscope (Nikon Corporation, Tokyo, Japan). The stain of RON was scored depending on the staining proportion (0, 0-4%; 1, 5-24%; 2, 25-49%; 3, 50-74%; and 4, 75-100%) and staining intensity (the intensity of RON membrane staining: No staining, 0; weak staining, 1; moderate staining, 2; and strong staining, 3). Finally, a cumulative evaluation of scores based on the addition of the two results ranging from 0-7 was conducted. The total expression of RON was considered as overexpression with a score  $\geq$ 4 or normal expression with a score <4.

Cell line and cell culture. The human 5637 BC cell line was obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured at 37°C in a humidified atmosphere containing 5% CO<sub>2</sub> in RPMI-1640 medium containing 10% FBS, 2 mM L-glutamine and 100 U/ml penicillin.

Western blot analysis. Western blot analysis was performed as previously described (11). Cellular proteins ( $100 \mu g$ /sample) were separated by 8% or 12% SDS-PAGE under reduced conditions. Individual proteins were detected using the aforementioned primary antibodies followed by horseradish peroxidase-coupled secondary antibodies (cat. no. ab205718, dilution, 1:5,000; Abcam, Cambridge, MA, USA). Densitometry was analyzed using Quantity One software (version 4.4.02; Bio-Rad Laboratories, Inc., Hercules, CA, USA).

*Transfection of BC cells*. Gene silencing was performed using scrambled siRNA (cat. no. sc-37007, nominated as si-Scr) and human RON sequence-specific duplex siRNA (cat. no. sc-36434, nominated as si-RON), which were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). The 5637 cells were seeded into a plate when they were 50-60% confluent at the time of transfection. The 5637 cells were transfected with 75 pmol si-RON and si-Scr using Lipofectamine<sup>®</sup> 2000 (Thermo Fisher Scientific, Inc.), following the manufacturer's protocol. At 48 h after transfection, the expression of RON was analyzed via western blot analysis as previously stated.

*Cell viability assay.* Sensitivity of the cells to RON knockdown by si-RON was analyzed using the CCK-8. Briefly, a total of  $1 \times 10^4$ /well cells were seeded in 96-well plates in  $100 \,\mu$ l culture medium (RPMI-1640 with 10% FBS) for 24 h at 37°C and then transfected with si-RON and si-Scr as previously described. Following transfection, cells were cultured for 0, 24, 48, 72 h individually. The cells were then treated with 10 ul/well of CCK-8 solution and incubated for another 2 h at 37°C. The absorbance values of each well were measured using a Multiskan Go plate reader (Thermo Fisher Scientific, Inc.) at a wavelength of 450 nm. The experiment was performed in triplicate.



Flow cytometric assays for cell cycle distribution and apoptosis. Transfected cells  $(2x10^5)$  were harvested and fixed with 75% ethanol overnight at -20°C. The fixed cells were treated with 1 mg/ml RNase A (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) in darkness at 37°C for 30 min and with 50 µg/ml propidium iodide (PI; Sigma-Aldrich; Merck KGaA) for 30 min at 37°C. The cells were analyzed using a flow cytometer (FACScan; BD Biosciences, Franklin Lakes, NJ, USA) to investigate cell cycle distribution. Quadrant analysis was performed using the CellQuest Pro software (version 5.1; BD Biosciences, Franklin Lanes, NJ, USA)

The cell apoptosis assay was performed using an Annexin-V/Fluorescein Isothiocyanate Apoptosis Detection kit (BD Biosciences, Franklin Lakes, NJ, USA). Transfected cells were collected and washed twice with cold PBS prior to staining with Annexin V and PI solution for 15 min in darkness at room temperature. The ratios of apoptotic cells were determined using a flow cytometer (FACScan; BD Biosciences).

*Wound healing assay.* Cells from the si-RON and the si-Scr groups were incubated in RPMI-1640 with 10% FBS in 6-well plates. Following transfection with si-RON or si-Scr, a small wound area was produced in the 90% confluent monolayer using a 200- $\mu$ l pipette tip in a lengthwise stripe. Following incubation at 37°C for 24 h, the area covered by migrated cells was examined under a light microscope (Nikon Corporation) and images were captured at x100 magnification. Experiments were repeated in triplicate.

Statistical analysis. Statistical analyses were performed using the SPSS software package (version 20; IBM Corp., Armonk, NY, USA). Data are presented as the mean  $\pm$  standard deviation. Statistical analysis was conducted using the Student's t-test for paired samples and the  $\chi^2$ -test was used for univariate analysis of RON proteins. P<0.05 was considered to indicate a statistically significant difference.

### Results

*Expression of RON protein in BC and paraneoplastic tissues*. The presence of RON protein was observed in the plasma membrane of BC cells, whereas the paraneoplastic tissues exhibited negative or low staining (Fig. 1). The association between total RON expression and clinical parameters was analyzed. As summarized in Table I, the positive expression rates of the RON was 54.7% (58/106) in BC cases and 17.6% (6/34) in paraneoplastic tissues. RON overexpression was positively associated with the number of tumors the patient had, histological grading, pathological stage and distant metastasis. No statistical differences were observed between RON overexpression and characteristics of age and sex.

Knockdown of RON inhibits cell proliferation in the 5637 cells. It was previously determined that the level of RON expression in 5637 cells was high (11), therefore 5637 cells were selected for future studies. To confirm the knockdown efficiency of si-RON, si-RON was transiently transfected into the 5637 cells. As depicted in Fig. 2A and B, at 48 h following transfection, the protein expression level of RON



Figure 1. IHC staining of RON in BC tissue sections (A) Representative IHC staining for RON expression in BC tissues. (B) Negative IHC staining in paraneoplastic tissues. Original magnification, x400. IHC, immunohistochemical; RON, macrophage stimulating 1 receptor; BC, bladder cancer.

was significantly downregulated by transfection with si-RON, compared with si-Scr (P<0.01). A CCK-8 assay was performed to analyze the proliferation rate of the 5637 cells following silencing of RON. The results of the CCK-8 assay demonstrated that si-RON notably inhibited cell proliferation, compared with cells treated with si-Scr (Fig. 2C, P<0.05).

Downregulation of RON expression inhibits 5637 cell migration. To assess whether the downregulation of RON affected the cellular migration, a wound-healing assay was conducted on the 5637 cells in the si-RON and si-Scr groups. As depicted in Fig. 3, the number of migrated cells in the si-RON group (47.37 $\pm$ 7.02%) was significantly lower than that in the si-Scr group (65.00 $\pm$ 5.57%) at 24 h (P<0.05) once the wound was produced on the cell monolayer, which indicated that the downregulation of RON expression could significantly decrease the migration of 5637 cells.

*Knockdown of RON promotes apoptosis in the 5637 cells.* Flow cytometry was performed to investigate whether the knockdown of RON increased the proportion of apoptotic 5637 cells. Flow cytometric analysis indicated that the proportion of early and late apoptotic cells were significantly increased in cells in the si-RON group, compared with those in si-Scr group (Fig. 4A and B; P<0.01).

Knockdown of RON induces cell cycle arrest at the  $G_1/S$  phase in the 5637 cells. Owing to the growth inhibitory response of si-RON treatment in 5637 cells, the effect of this treatment on the cell cycle distribution was studied. The 5637 cells were incubated with si-RON or si-Scr for 48 h, following which cell cycle analysis was performed. The proportions of si-RON group cells were significantly reduced in S phase and increased in G1 phase, compared with those of si-Scr cells (Fig. 5A and B; P<0.05). Furthermore, the effects of RON on CDKs and CDK inhibitors (CDKIs) were evaluated, which are involved in regulation of cell cycle arrest in BC cells (11). The 5637 cells treated with si-RON exhibited an increased expression of p27 and p21, whereas the expression of cyclin D1, cyclin D3 and CDK4 were decreased compared with cells transfected with si-Scr (Fig. 5C).

Knockdown of RON decreases the phosphorylation of Akt and mitogen-activated protein kinases (MAPKs) in 5637 cells. To investigate the potential signaling pathways involved

		RON ex	pression			
Variables	Patients, n	Low	High	$\chi^2$ -value	P-value	
Tissue				15.54	0.000	
All tumor	106	48	58			
Paracancerous	34	28	6			
Sex				2.749	0.097	
Male	87	41	46			
Female	19	5	14			
Age, years				0.197	0.657	
<70	51	21	30			
≥70	55	25	30			
Number of tumor nodules				9.348	0.002	
Single	63	35	28			
Multiple	43	11	32			
Distant metastasis				7.323	0.007	
M0	90	44	46			
M1	16	2	14			
Pathological stage				4.652	0.031	
$T_{is}$ - $T_1$	42	28	14			
$T_{2}-T_{4}$	64	29	35			
Histological grading				9.667	0.008	
Urothelial carcinoma, grade I	10	8	2			
Urothelial carcinoma, grade II	41	25	16			
Urothelial carcinoma, grade III	55	20	35			

Table I.	Association	between th	ie RON e	xpression	and the	clinical	pathological	features in	n bladder	cancer.

RON, macrophage stimulating 1 receptor; T, tumor; M, metastasis.

in RON-mediated cellular migration, apoptosis and cell cycle arrest, the phosphoinositide 3-kinase (PI3K)-Akt and MAPK pathways were selected for further study as the two pathways are responsible for cell proliferation, migration, apoptosis and cell cycle arrest (12). As depicted in Fig. 6, the phosphorylation levels of Akt, ERK1/2 and p38 in the si-RON group of 5637 cells were lower, than those in the si-Scr group at 48 h. The levels of total Akt, ERK1/2 and p38 appeared unchanged.

## Discussion

The aberrant expression of RON has been verified to serve a notable role in the development and progression of colon, breast, bladder and pancreatic cancer, and other types of epithelial cancer (7-14). Overexpression of RON is associated with poor pathological characteristics in these cancer types (15). In the present study, 106 BC clinical specimens were examined for RON expression. The majority of patient specimens (54.7%) were determined to be positive for RON expression, and the level of RON expression in the cancer tissues was significantly higher than that in the adjacent tissues (Fig. 1). Subsequently, analysis of the association between the expression of RON and clinicopathological features revealed that the positive

expression rate of RON protein was closely associated with the number of tumors, distant metastasis, histological grading and pathological stage (Table I). Cheng *et al* (9) previously reported that RON was overexpressed in only 32.8% of analyzed BC samples. The disparity in results between the study by Cheng *et al* (9) and the present study could be attributed to the difference in antibodies used to detect RON expression, and different criteria used to interpret the results. In the present study, the level of RON expression was evaluated in a standardized and semi-quantitative manner using the mAb zt/f2, which is frequently regarded as an effective tool in immunochemistry for its high reactivity, specificity and minimal background in human tissue sections (15).

Overexpression of RON is associated with oncogenic properties, including the promotion of cellular proliferation, migration, invasion and survival in several human cancer cell lines (16-19). To verify the potential role of RON in BC cells, its expression level in BC cell lines was analyzed and the 5637 cells were selected for further study as they have a relatively high RON expression (11). Subsequently, si-RON was used to knockdown RON expression in the 5637 cells (Fig. 2A). The results indicated that knockdown of RON could notably inhibit cellular proliferation (Fig. 2B) and decrease migration (Fig. 3).





Figure 2. Silencing RON impaired BC cell proliferation. Silencing RON impaired BC cell proliferation. Western blot analysis results indicated RON specific siRNA significantly downregulated the protein expression level. (A) The effect of RON siRNA on RON protein expression level using western blotting and (B) quantification of RON protein expression level in 5637 cells. (C) CCK-8 assay was performed following RON siRNA treatment. A reduction in absorbance was observed upon treatment with si-RON, when compared with si-Scr. Values are presented as the mean  $\pm$  standard deviation from three independent experiments. \*P<0.05 and \*\*P<0.01, compared with si-Scr group. RON, macrophage stimulating 1 receptor; si-Scr, scramble small interfering RNA; si-RON, human RON sequence-specific duplex siRNA; OD, optical density.



Figure 3. Downregulation of RON expression inhibited the migration of the 5637 cells. (A) A wound-healing assay was performed on si-RON- and si-Scr-treated 5637 cells. (B) The proportion of migrated cells in the si-RON group (47.33 $\pm$ 7.02%) was significantly less than those of si-Scr group (65.00 $\pm$ 5.57%) at 24 h (\*P<0.05) following the wound being produced on the monolayer cells. The percentage of the wounded area covered by the migrated cells was measured. Data depicted here are from one of three experiments with similar results. RON, macrophage stimulating 1 receptor; si-Scr, scramble small interfering RNA; si-RON, human RON sequence-specific duplex siRNA.



Figure 4. Silencing RON induced apoptosis in 5637 cells. Flow cytometry was used to detect the proportion of cells in early and late apoptosis following transfection with si-RON, and compared with si-Scr. (A) Cells were transfected with si-RON or si-Scr for 48 h, collected, stained with Annexin V and PI and then analyzed by flow cytometry. (B) Quantitative results were obtained using Annexin V/PI staining. Data are derived from three independent experiments and are expressed as the mean ± standard deviation. \*\*P<0.01, compared with si-Scr group. FITC, fluorescein isothiocyanate; RON, macrophage stimulating 1 receptor; si-Scr, scramble small interfering RNA; si-RON, human RON-targeting small interfering RNA; PI, propidium iodide.



Figure 5. Silencing RON induced cell cycle arrest in 5637 cells. Silencing RON induced cell cycle arrest in the 5637 cells. (A) Representative results of flow cytometric analysis. (B) Quantitative analysis of cell cycle distribution of the 5637 cells treated with si-RON or si-Scr. (C) Representative western blot analysis demonstrated changes in the expression of cyclins, cyclin-dependent kinases and cyclin-dependent protein kinase inhibitors following si-RON or si-Scr treatment in the 5637 cells. \*P<0.05, compared with si-Scr group. Values are presented as the mean ± standard deviation from three independent experiments. RON, macrophage stimulating 1 receptor; si-Scr, scramble small interfering RNA; si-RON, human RON sequence-specific duplex siRNA; CDK4, cyclin dependent kinase 4.





Figure 6. Silencing RON decreased Akt and MAPK phosphorylation in the 5637 cells. Western blot analysis measured the effects of RON knockdown on the phosphorylation levels of Akt, ERK1/2 and p38. Akt, protein kinase B; MAPK, mitogen-activated protein kinase; RON, macrophage stimulating 1 receptor; ERK1/2, extracellular signal-regulated kinase 1/2.

The potential functions of RON in the regulation of cell apoptosis and cell cycle progression have been investigated in several cancer cell lines (20-22). However, there is limited information regarding the influence of RON on apoptosis and cell cycle progression in human BC. In the present study, RON knockdown promoted apoptosis and induced G<sub>1</sub>/S arrest in the 5637 cells (Figs. 4 and 5). CDKs and cyclins serve a crucial role in the regulation of cell cycle progression (23,24). The G<sub>1</sub> cyclin-CDK complex cyclin D-CDK4/6 induces a transition from  $G_1$  to S phase (25). CDKIs have been regarded as putative tumor suppressors (26). p21 and p27 are CDKIs that bind to cyclin-CDK complexes to inactivate them, inhibiting cell cycle progression (26). The results indicated that RON knockdown promoted G<sub>1</sub>/S arrest via the downregulation of cyclin D1, cyclin D3 and CDK4, and the upregulation of p21 and p27, indicating that RON serves a vital role in regulating cell cycle-associated proteins in BC (Fig. 5C).

RON signaling is conventionally transmitted by the RAS-MAPK cascade and the PI3K-Akt pathway (12). Activation of the PI3K-Akt pathway is involved in RON-mediated cell apoptosis, proliferation, migration and cell matrix invasion (12,27,28). Furthermore, RON-mediated MAPK signaling cascade directs various cellular programs, including cell growth, migration, survival and differentiation (12,19,28,29). To observe whether si-RON inhibited downstream signal transduction, si-RON and si-Src were transfected into the 5637 cells. Data indicated that the Ser473 phosphorylation levels on Akt and the phosphorylation of

ERK1/2 and p38 were significantly decreased by RON knockdown in these cells (Fig. 6). Considering these results, it appears likely that si-RON induced the inhibition of Akt and MAPK phosphorylation; these processes are involved in phenotypic changes to 5637 cells, including inhibition of cell proliferation and motility, induction of  $G_1$ /S cell cycle arrest and increased apoptosis. Knockdown of RON by siRNA affected the phosphorylation level of Akt, ERK1/2 and p38; however, the more complicated mechanisms underlying the Akt and MAPK signaling pathways following RON knockdown require further investigation in future studies.

In summary, the data produced in the present study indicated that RON was overexpressed in BC and was associated with poor pathological features. Knockdown of RON regulates BC cell behaviors through the modulation of Akt and MAPK signaling in human BC cells. These results indicate that RON is a potential target for therapeutic intervention in BC and have provided an experimental basis for future investigations.

#### Acknowledgements

Not applicable.

## Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81272828 to Dr QM), Zhejiang Provincial Foundation for Medical and Health Sciences (grant nos. 2016KYB263 and 2014KYB355 to Dr QM, and grant no. 2017KY576 to Dr JFC) and Ningbo Natural Science Foundation (grant no. 2015A610224 to Dr JFC, and grant no. 2016A610159 to Dr XYL).

#### Availability of data and materials

The authors declare that the datasets generated are all included in the current study and are available from the corresponding author on reasonable request.

## Authors' contributions

JFC participated to the experimental design, interpreted the results and wrote the manuscript; BXY, LM and XYL performed experiments and analyzed the results; JHJ coordinated the experimental work, interpreted the results and contributed to the critical revision; QM designed the research plan, interpreted the results and wrote the manuscript.

#### Ethics approval and consent to participate

Not applicable.

## **Consent for publication**

Not applicable.

## **Competing interests**

The authors declare that they have no competing interests.

6554

#### References

- Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin 67: 7-30, 2017.
- Martin-Doyle W and Kwiatkowski DJ: Molecular biology of bladder cancer. Hematol Oncol Clin North Am 29: 191-203, 2015.
- 3. Bellmunt J, Powles T and Vogelzang NJ: A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treat Rev 54: 58-67, 2017.
- 4. Pinto IG: Systemic therapy in bladder cancer. Indian J Urol 33: 118-126, 2017.
- Mohammed AA, El-Tanni H, El-Khatib HM, Mirza AA, Mirza AA and Alturaifi TH: Urinary bladder cancer: Biomarkers and target therapy, new era for more attention. Oncol Rev 10: 320, 2016.
- Wang MH, Padhye SS, Guin S, Ma Q and Zhou YQ: Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy. Acta Pharmacol Sin 31: 1181-1188, 2010.
- Park YL, Lee GH, Kim KY, Myung E, Kim JS, Myung DS, Park KJ, Cho SB, Lee WS, Jung YD, *et al*: Expression of RON in colorectal cancer and its relationships with tumor cell behavior and prognosis. Tumori 98: 652-662, 2012.
- Feres KJ, Ischenko I and Hayman MJ: The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells. Oncogene 28: 279-288, 2009.
- Cheng HL, Liu HS, Lin YJ, Čhen HH, Hsu PY, Chang TY, Ho CL, Tzai TS and Chow NH: Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer 92: 1906-1914, 2005.
  Hsu PY, Liu HS, Cheng HL, Tzai TS, Guo HR, Ho CL and
- Hsu PY, Liu HS, Cheng HL, Tzai TS, Guo HR, Ho CL and Chow NH: Collaboration of RON and epidermal growth factor receptor in human bladder carcinogenesis. J Urol 176: 2262-2267, 2006.
- 11. Chen JF, Yu BX, Yu R, Ma L, Lv XY, Cheng Y and Ma Q: Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis. Oncol Rep 37: 721-728, 2017.
- Yao HP, Zhou YQ, Zhang R and Wang MH: MSP-RON signaling in cancer: Pathogenesis and therapeutic potential. Nat Rev Cancer 13: 466-481, 2013.
- Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE and Lowy AM: The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 67: 6075-6082, 2007.
- Zarei O, Benvenuti S, Ustun-Alkan F, Hamzeh-Mivehroud M and Dastmalchi S: Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery. J Cancer Res Clin Oncol 142: 2429-2446, 2016.

- Wang MH, Lee W, Luo YL, Weis MT and Yao HP: Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumorigenic phenotypes in thyroid cancer cells. J Pathol 213: 402-411, 2007.
- Wagh PK, Peace BE and Waltz SE: Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 100: 1-33, 2008.
- Camp ER, Liu W, Fan F, Yang A, Somcio R and Ellis LM: RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol 12: 273-281, 2005.
- Wang MH, Wang D and Chen YQ: Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 24: 1291-1300, 2003.
- Danilkovitch-Miagkova A: Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets 3: 31-40, 2003.
- 20. Chung CY, Park YL, Song YA, Myung E, Kim KY, Lee GH, Ki HS, Park KJ, Cho SB, Lee WS, *et al*: Knockdown of RON inhibits AP-1 activity and induces apoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells. Dig Dis Sci 57: 371-380, 2012.
- 21. Song YA, Park YL, Kim KY, Myung E, Chung CY, Cho SB, Lee WS, Jung YD, Kweon SS and Joo YE: RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer. Pathol Int 62: 127-136, 2012.
- 22. Cho SB, Park YL, Song YA, Kim KY, Lee GH, Cho DH, Myung DS, Park KJ, Lee WS, Chung IJ, *et al*: Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells. Oncol Rep 26: 1581-1586, 2011.
- 23. Morgan DO: Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13: 261-291, 1997.
- 24. Murray AW and Marks D: Can sequencing shed light on cell cycling? Nature 409: 844-846, 2001.
- Connell-Crowley L, Elledge SJ and Harper JW: G1 cyclin-dependent kinases are sufficient to initiate DNA synthesis in quiescent human fibroblasts. Curr Biol 8: 65-68, 1998.
- 26. Vermeulen K, van Bockstaele DR and Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36: 131-149, 2003.
- 27. Huang Y, Hu J, Zheng J, Li J, Wei T, Zheng Z and Cheng Y: Down-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin. J Exp Clin Cancer Res 31: 48, 2012.
- Wang MH, Zhang R, Zhou YQ and Yao HP: Pathogenesis of RON receptor tyrosine kinase in cancer cells: Activation mechanism, functional crosstalk, and signaling addiction. J Biomed Res 27: 345-356, 2013.
- 29. Lu Y, Yao HP and Wang MH: Multiple variants of the RON receptor tyrosine kinase: Biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett 257: 157-164, 2007.